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Whether the bone marrow microenvironment can contribute to development of blood borne cancers is
controversial. In a recent issue of Nature, Raaijmakers et al. (2010) show that deletion of Dicer1 specifically
in osteoprogenitors not only impaired their differentiation but also resulted in disrupted blood formation and
secondary leukemia.In the marrow, hematopoietic stem cells
(HSCs) reside in specific microenviron-
ments, or niches, that regulate HSC prolif-
eration and quiescence (Taichman, 2005).
Cells that give rise to the sinusoidal endo-
thelium (Kiel et al., 2005) and cells in the
osteoblastic lineage play important roles
in establishing the HSC niche (Calvi et al.,
2003; Taichman, 2005; Zhang et al.,
2003); however, the precise contribution
of each separate niche cell population is
poorly defined. It is also unclear whether
the vasculature and bone compartments
comprising the HSC niche are directly
involved in malignant processes—do
hematopoietic malignancies co-opt the
normal HSC niche for their survival or do
they create their own niche? In a recent
study published in Nature, Raaijmakers
et al. (2010) demonstrate that cellular
dysfunction restricted to the bone
compartment lead to the development of
hematopoietic malignancies (Figure 1).
Osteoblasts are derived from pluripo-
tent mesenchymal stem cells that differ-
entiate to become highly specialized syn-
thetic cells that respond to mechanical,
systemic, and local stimuli to orchestrate
mineralization and bone remodeling.
Raaijmaker et al. deleted the RNase III
enzyme Dicer1, which is required for
miRNA- and siRNA-dependent gene
silencing (Lee et al., 2004) specifically
in osteoprogenitor cells. This was ac-
complished by crossing mice expressing
green fluorescent protein (GFP)-Cre re-
combinase driven by theOsterix promoter
(expressed first in osteoprogenitor cells)
with mice with floxed Dicer1 alleles
(OCDfl/fl mice). The authors found that
Dicer1 deletion in the osteoprogenitors
was associated with reduced expression
of the mature osteoblast marker Osteo-calcin in the bone, an altered bone matrix,
and a reduced ability of bone marrow
stromal cells to produce mineral in vitro.
The Dicer1 deletion was not detected in
cells of the hematopoietic lineages, and
there were no significant differences in
HSC numbers or HSC function between
OCDfl/fl and control mice. However, when
Raaijmaker and colleagues analyzed
blood formation in the OCDfl/fl mice, they
found signs of ineffective hematopoiesis
consistent with development of myelo-
dysplastic syndrome (MDS). This complex
humandisease is characterizedbyperiph-
eral cytopenia, dysgranulopoiesis, and
dysplastic megakaryocytes, all of which
were found in theOCDfl/flmice. In addition,
accelerated apoptosis and proliferation
was observed exclusively in hematopoi-
etic progenitors along with reduced
numbers of B cell and B cell progenitors.
The phenotype of the OCDfl/fl mice sug-
gested that themarrowmicroenvironment
was the root causeof these hematopoietic
dysfunctions, and the authors next per-
formed reciprocal bone marrow trans-
plants to assess whether this was indeed
the case. In these experiments, hemato-
poietic cells from OCDfl/fl mice recovered
when transplanted into a wild-type envi-
ronment, andconversely,wild-typehema-
topoietic cells developed the myelodys-
platic phenotype when transplanted into
the mutant mice. Strikingly, when the
authors placed the Dicer1 deletion under
control of the Osteocalcin promotor, no
hematopoietic abnormalities were identi-
fied, suggesting that dysfunction specifi-
cally in osteoprogenitor cells lead to the
hematopoietic defects.
Some of the OCDfl/fl mice developed
myeloid sarcomas, indicative of develop-
ment of acute myelogenous leukemiaCell Stem C(AML). Genomic analysis of the tumors re-
vealed genetic abnormalities consistent
with clonal evolution of tumor cells, but
also showed that Dicer1 had not been
deleted in the cancer cells, providing
direct evidence for an instructive role of
the microenvironment in tumorigenesis.
In some cases, abnormal amplification
of a common (27 kilobase [kb]) region on
chromosome 14qC1 was observed;
however, the biological significance of
this finding is unknown. To gain insights
into the molecular pathways underlying
the hematopoietic phenotype of OCDfl/fl
mice, Raaijmaker et al. compared gene
expression profiles of osteoblast progen-
itors. These experiments revealed that
the Shwachman-Diamond-Bodian syn-
drome (Sbds) gene was significantly
downregulated in OCDfl/fl osteolineage
cells. Shwachman-Diamond-Bodian syn-
drome is a rare autosomal-recessive
disease characterized by pancytopenia,
increased risk forMDS and AML, exocrine
pancreatic insufficiency, and immuno-
logic, hepatic, cardiac, and skeletal disor-
ders (Burroughs et al., 2009). Notably, the
authors found that deleting the Sbds gene
in the osteoprogenitor cells recapitulated
the phenotype of the OCDfl/fl mice,
suggesting that the bone microenviron-
ment plays an instructive role in the
pathogenesis of Shwachman-Diamond-
Bodian syndrome.
Taken together, these studies demon-
strate that osteoprogenitor cells in the
marrow microenvironment are able to
promote tumorigenesis of hematopoietic
cells but that terminally differentiated
osteoblasts in contrast do not have this
ability. Although these findings highlight
important differences in niche regulation
between immature andmature bone cells,ell 6, May 7, 2010 ª2010 Elsevier Inc. 399
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Figure 1. Dysfunctional Bone Progenitors Cause Hematopoietic Malignancies
Mesenchymal stem cells give rise to osteoblastic lineage cells where preosteoblasts expressOsterix (Osx)
and mature osteoblasts express high levels of Osteocalcin (OCN) and Osx. Deletion of the RNase III
enzyme Dicer1specifically in preosteoblasts, but not in mature osteoblasts, resulted in alterations in oste-
oblast function and bone matrix concomitant with development of myelodysplastic syndrome (MDS),
acute myelogenous leukemia (AML), and myeloid sarcomas.
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Previewsit seems likely that the process of
advancing MDS/AML may be quite
distinct from the ability to support normal
hematopoiesis, thus whether specific
osteoblastic-lineage populations play
discrete roles during the normal formation
and maintenance of the HSC niche
remains unclear. The transcriptome anal-
ysis revealed that deletion of Dicer1
affected pathways known to regulate
osteoblastic lineage commitment and
differentiation, but also showed differen-
tial expression of stress response genes
and cytokines. These data may help to
delineate on a molecular level how cross-
talk between HSCs and niche cells may
regulate niche function. For example, it
has recently been reported that HSCs
are able to secrete bone morphogenetic
proteins (BMPs) that regulate osteoblastic
differentiation (Jung et al., 2008). Thus,
Dicer1 deleted osteoprogenitors may400 Cell Stem Cell 6, May 7, 2010 ª2010 Elslack the ability to respond to HSC-derived
signals. The hematopoietic defects ob-
served in the OCDfl/fl mice could also be
the result on the abnormal bone pheno-
type. Bone matrix is an abundant source
of many hematopoietic-active proteins
including BMPs, byglycan, granulocyte
macrophage colony stimulating factor,
insulin-like growth factors, and osteopon-
tin (reviewed in Taichman, 2005). It is
possible that Dicer-deficient osteoproge-
nitors are less efficient at presenting
HSCs with matrix bound active proteins
and that alterations in exposure to these
molecules was the underlying mechanism
driving leukemogenesis. The Raaijmakers
et al. report also established tools to delin-
eate what signals produced by osteopro-
genitors support normal HSC activities
and if one niche supports all hematopoi-
etic functions, or does the niche change
during hematopoietic development?evier Inc.Importantly, the current work by Raaij-
makers et al. provides a link between
human disease and their findings. The
downregulation ofSbds gene in osteopro-
genitors gave rise to MDS features,
lending support to the idea that the niche
itself may contribute to the formation of
these secondary tumors. If these findings
reflect the human condition, under-
standinghownichesignals regulate leuke-
mogenesis will take on new therapeutic
importance. In addition, secondary leuke-
mias occur in a subset of patients after
allogeneic stem cell transplantation. If
the niche is a driving force behind these
tumors, niche-directed therapies will
need to be developed to prevent long-
term relapse in these patients. In conclu-
sion, understanding how diverse signals
emanate from the niche is critical to com-
prehend the functional interrelationships
between skeletal tissues and hematopoi-
esis and how their interplay contributes
to human disease.REFERENCES
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